Trial Profile

Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Obesity; Prediabetic state
Focus Registrational; Therapeutic Use
Acronyms STEP 10
Sponsors Novo Nordisk

Most Recent Events

01 Dec 2023 This trial has been completed in Denmark and Finland.
20 Jul 2023 Status changed from active, no longer recruiting to completed.
10 Nov 2022 Planned End Date changed from 24 Jul 2023 to 4 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com